Patents Assigned to Cadila Healthcare Limited
-
Publication number: 20200071287Abstract: The present invention relates to a process for the preparation of apalutamide. In particular, the present invention relates to a process for the preparation of apalutamide and its intermediates. The present invention also relates to pharmaceutical compositions comprising apalutamide.Type: ApplicationFiled: March 27, 2019Publication date: March 5, 2020Applicant: CADILA HEALTHCARE LIMITEDInventors: Kumar Kamlesh SINGH, Nikhil Amar SINGH, Ganpat Dan Shimbhu CHARAN, Nimeshkumar Mukeshkumar SHAH
-
Patent number: 10550150Abstract: The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, their pharmaceutically accepted salts, or prodrugs thereof which are useful in the treatment or prevention of diseases in which the Kappa (?) opioid receptors (KOR) are involved, such as treatment or prevention of visceral pain, hyperalgesia, rheumatoid arthritic inflammation, osteoarthritic inflammation, IBD inflammation, IBS inflammation, ocular inflammation, otitic inflammation or autoimmune inflammation. The invention also relates to process for the manufacture of said short-chain peptides, and pharmaceutical compositions containing them and their use.Type: GrantFiled: May 9, 2016Date of Patent: February 4, 2020Assignee: CADILA HEALTHCARE LIMITEDInventors: Ranjit Desai, Rajesh Bahekar, Vijay Prajapati, Rajendra Chopade
-
Publication number: 20200024250Abstract: The present invention relates to a process for the preparation of apalutamide. In particular, the present invention relates to a process for the preparation of apalutamide and its intermediates. The present invention also relates to pharmaceutical compositions comprising apalutamide.Type: ApplicationFiled: September 27, 2019Publication date: January 23, 2020Applicant: CADILA HEALTHCARE LIMITEDInventors: Kumar Kamlesh SINGH, Nikhil Amar SINGH, Ganpat Dan Shimbhu CHARAN, Nimeshkumar Mukeshkumar SHAH
-
Publication number: 20190359574Abstract: The present invention relates to an improved process for the preparation of quinolone based compounds of general formula (I) using intermediate compound of general formula (XII). Invention also provides an improved process for the preparation of compound of formula (I-a) using intermediate compound of formula (XII-a) and some novel impurities generated during process. Compounds prepared using this process can be used to treat anemia.Type: ApplicationFiled: May 24, 2019Publication date: November 28, 2019Applicant: CADILA HEALTHCARE LIMITEDInventors: Ranjit C. Desai, Rajiv Sharma, Vrajesh Pandya, Kalpesh Shah, Sunil Patel, Rakesh Chauhan, Ranjeet Nair, Vivek Joshi, Manoj Patel, Mrigendra Shukla
-
Patent number: 10435363Abstract: The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.Type: GrantFiled: December 1, 2016Date of Patent: October 8, 2019Assignee: Cadila Healthcare LimitedInventors: Shriprakash Dhar Dwivedi, Ramesh Chandra Singh, Rajendra Gokalbhai Chavda, Jagdish Maganlal Patel, Daya Ram Pal, Pranav Jitendra Gangwar, Vikas Patel, Vishwadeepak Rama Pati Tripathi
-
Patent number: 10414741Abstract: The present invention relates to an amorphous vortioxetine and salts thereof. In particular, the invention relates to a process for the preparation of an amorphous vortioxetine hydrobromide. Further, the invention also relates to a process for preparation of amorphous vortioxetine free base. The invention also relates to pharmaceutical compositions comprising an amorphous vortioxetine or hydrobromide salt thereof for oral administration for treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD).Type: GrantFiled: September 30, 2014Date of Patent: September 17, 2019Assignee: CADILA HEALTHCARE LIMITEDInventors: Shri Prakash Dhar Dwivedi, Kumar Kamlesh Singh, Jitendra Maganbhai Gajera, Dinesh Kumar Raikwar, Brij Khera
-
Publication number: 20190275102Abstract: The present invention relates to sterile injectable compositions comprising carfilzomib and one or more phospholipids. The present invention also relates to processes for preparing the sterile injectable compositions.Type: ApplicationFiled: March 5, 2019Publication date: September 12, 2019Applicant: CADILA HEALTHCARE LIMITEDInventors: Kannan Essakimuthu MUTHAIYYAN, Debjani Manoj SINGH, Nirav Ishwarlal KHATRI, Omprakash Ganesh Ram SHARMA
-
Patent number: 10385017Abstract: The present invention relates to compositions comprising saroglitazar magnesium wherein the saroglitazar magnesium has a purity of greater than or equal to 99% by weight, and dimer compound of Formula (IV) present in an amount relative to saroglitazar magnesium less than about 0.3% by weight by area percentage of HPLC. The present invention also related to the process for the preparation thereof and pharmaceutical compositions comprising the same.Type: GrantFiled: October 13, 2016Date of Patent: August 20, 2019Assignee: Cadila Healthcare LimitedInventors: Sanjay Jagdish Desai, Ramesh Chandra Singh, Daya Ram Pal, Dharmendra Arvindbhai Darji
-
Publication number: 20190224332Abstract: The present invention relates to sterile injectable compositions comprising drug-phospholipid micelles. The present invention also relates to processes for the preparation of the sterile injectable compositions.Type: ApplicationFiled: September 6, 2017Publication date: July 25, 2019Applicant: CADILA HEALTHCARE LIMITEDInventors: Sushilkumar Dhanaji PATIL, Smita Amarjitsing RAJPUT, Nirav Ishwarlal KHATRI, Alex Kochukunju GEORGE, Sushrut Krishnaji KULKARNI
-
Patent number: 10358440Abstract: The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.Type: GrantFiled: February 13, 2019Date of Patent: July 23, 2019Assignee: Cadila Healthcare LimitedInventors: Sanjay Jagdish Desai, Jayprakash Ajitsingh Parihar, Alpesh Pravinchandra Shah
-
Publication number: 20190202814Abstract: The present invention relates to processes for the preparation of empagliflozin. In particular, the present invention relates to the preparation of empagliflozin and intermediates thereof. The present invention also relates to co-crystal of empagliflozin and amino acid and amorphous form of empagliflozin.Type: ApplicationFiled: March 7, 2019Publication date: July 4, 2019Applicant: CADILA HEALTHCARE LIMITEDInventors: Sanjay Jagdish DESAI, Jayprakash Ajitsingh PARIHAR, Mahesh Laljibhai RUPAPARA, Pranav Jitendra GANGWAR, Hardik Bhikhubhai GHODASARA
-
Publication number: 20190177309Abstract: The present invention relates to Brexpiprazole having a purity of about 99.5% or more by area percentage of HPLC, having total impurities not more than 0.5% relative to brexpiprazole as measured by area percentage of HPLC, and having less than 0.1% 1-(benzo[b]thiophen-4-yl)piperazine or a salt thereof relative to brexpiprazole by area percentage of HPLC. The present invention also provides a composition comprising brexpiprazole having 1-(benzo[b]thiophen-4-yl)-piperazine or a salt thereof in an amount less than about 0.1% relative to brexpiprazole by area percentage of HPLC and process for the preparation of brexpiprazole.Type: ApplicationFiled: February 13, 2019Publication date: June 13, 2019Applicant: CADILA HEALTHCARE LIMITEDInventors: Sanjay Jagdish DESAI, Jayprakash Ajitsingh PARIHAR, Alpesh Pravinchandra SHAH
-
Patent number: 10315993Abstract: The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.Type: GrantFiled: April 25, 2018Date of Patent: June 11, 2019Assignee: Cadila Healthcare LimitedInventors: Mukul R. Jain, Suresh Giri, Himanshu M. Kothari, Kaushik Banerjee, Rashmikant Kachhiya
-
Patent number: 10246470Abstract: The present invention relates to a compound (3S)-3-(4-((3-(6-Oxa-3-azabicyclo[3.1.1]heptan-3-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoic acid methods for use of this and other compounds.Type: GrantFiled: June 7, 2018Date of Patent: April 2, 2019Assignee: CADILA HEALTHCARE LIMITEDInventors: Ranjit C. Desai, Brijeshkumar Srivastava
-
Publication number: 20180360817Abstract: The present invention provides an extended release osmotic tablet dosage form comprising methylphenidate hydrochloride (MPH). The dosage form comprises a core tablet comprising methylphenidate hydrochloride in an amount of more than 8% by weight of the core tablet; a semi-permeable membrane surrounding the core tablet, and an immediate release drug coat comprising methylphenidate hydrochloride surrounding the semipermeable membrane.Type: ApplicationFiled: December 30, 2016Publication date: December 20, 2018Applicant: CADILA HEALTHCARE LIMITEDInventors: Manish CHAWLA, Shailesh Vishwanath BIRADAR, Mayur LOYA, Jayendrakumar Dasharathlal PATEL, Akshay Virendra AGARWAL
-
Publication number: 20180346486Abstract: The present invention relates to a compound (3S)-3-(4-((3-(6-Oxa-3-azabicyclo [3.1.1]heptan-3-ylmethyl)benzyl)oxy)phenyl)hex-4-ynoic acid methods for use of this and other compounds.Type: ApplicationFiled: June 7, 2018Publication date: December 6, 2018Applicant: CADILA HEALTHCARE LIMITEDInventors: Ranjit C. DESAI, Brijeshkumar SRIVASTAVA
-
Patent number: 10112898Abstract: The present invention relates to an improved process for the preparation of pyrroles derivatives having hypolipidemic and hypocholesteremic activities. In particular, the invention relates to an improved process for the preparation of 2-ethoxy-3-(4-(2-(2-methyl-5-(4-(methylthio)phenyl)-1H-pyrrol-1-yl)ethoxy)phenyl)propanoate and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also relates to an improved process for the preparation of mesylate compound (A1).Type: GrantFiled: September 5, 2014Date of Patent: October 30, 2018Assignee: Cadila Healthcare LimitedInventors: Shri Prakash Dhar Dwivedi, Ramesh Chandra Singh, Jagdish Maganlal Patel, Vikas Patel, Vishwadeepak Rama Pati Tripathi, Pranav Jitendra Gangwar, Jigar Mukundbhai Raval
-
Patent number: 10098868Abstract: The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7. formula (I).Type: GrantFiled: March 31, 2017Date of Patent: October 16, 2018Assignee: Cadila Healthcare LimitedInventors: Jitendre D. Patel, Prakash Davadra, Snehal Patel, Shafiq Sheikh
-
Patent number: 10093728Abstract: The present invention provides certain improved formulations of proteins. Specifically, the present invention provides use of certain excipients that are useful for stabilization of antibody preparations. Additionally, the novel formulations of the present invention prevents the formation of aggregates or fragments or modifications of protein in solution.Type: GrantFiled: March 5, 2013Date of Patent: October 9, 2018Assignee: CADILA HEALTHCARE LIMITEDInventors: Sanjeev Kumar Mendiratta, Sanjay Bandyopadhyay, Chintan G. Patel
-
Publication number: 20180271815Abstract: The present invention relates to a stable, aqueous, injectable solution comprising diclofenac and polyvinylpyrrolidone. The present invention also relates to processes for preparing the injectable solution.Type: ApplicationFiled: March 23, 2018Publication date: September 27, 2018Applicant: CADILA HEALTHCARE LIMITEDInventors: Sushilkumar Dhanaji PATIL, Nirav Ishwarlal KHATRI, Alex Kochukunju GEORGE, Sushrut Krishnaji KULKARNI